Revance to Participate in the 2017 Wells Fargo Securities Healthcare Conference
31 August 2017 - 6:05AM
Business Wire
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology
company developing botulinum toxin products for use in aesthetic
and therapeutic indications, today announced that the company will
participate in the 2017 Wells Fargo Securities Healthcare
Conference in Boston, MA.
President and Chief Executive Officer, Dan Browne, is scheduled
to participate in a fireside chat discussion on Wednesday,
September 6 at 3:35pm ET.
Interested parties can access the live audio webcast for this
conference from the Investor Relations section of the company's
website at www.revance.com. The webcast replay will be
available after the conclusion of the live presentation for
approximately 30 days.
About Revance Therapeutics, Inc.
Revance, a Silicon Valley-based biotechnology company, is
committed to the advancement of remarkable science. The company is
developing a portfolio of products for aesthetic medicine and
underserved therapeutic specialties, including dermatology,
orthopedics and neurology. Revance's science is based upon a
proprietary peptide technology, which when combined with active
drug molecules, may help address current unmet needs. Revance's
initial focus is on developing daxibotulinumtoxinA, the company's
highly purified botulinum toxin, for a broad spectrum of aesthetic
and therapeutic indications, including facial wrinkles and muscle
movement disorders.
The company's lead drug candidate, DaxibotulinumtoxinA for
Injection (RT002), is currently in development for the treatment of
glabellar lines, cervical dystonia and plantar fasciitis with the
potential to be the first long-acting neuromodulator. The company
holds worldwide rights to RT002 injectable and RT001 topical and
the pharmaceutical uses of its proprietary peptide technology
platform. More information on Revance may be found
at www.revance.com.
"Revance Therapeutics" and the Revance logo are registered
trademarks of Revance Therapeutics, Inc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170830005881/en/
Investors:Revance TherapeuticsJeanie Herbert,
714-325-3584jherbert@revance.comorBurns McClellanAmi Bavishi,
212-213-0006abavishi@burnsmc.comorTrade Media:Nadine Tosk,
504-453-8344nadinepr@gmail.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Apr 2024 to May 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From May 2023 to May 2024